A Multi-Center, Open Label, Expanded Access Trial Of Maraviroc
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE)
AEs as defined by the Division of AIDS (DAIDS) toxicity grading scale: Grade 3 = severe: interrupted usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 = very severe: events that were unacceptable and intolerable or were irreversable or caused imminent danger of death. If same participant had more than 1 occurrence in the same preferred term event category, only the most severe (grade 4) occurrence was taken. Treatment-related = investigator assessment of a reasonable possibility that the investigational product caused or contributed to the AE.
Baseline up to Week 144
Yes
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A4001050
NCT00426660
February 2007
June 2010
Name | Location |
---|---|
Pfizer Investigational Site | Birmingham, Alabama 35205 |
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Atlanta, Georgia 30342 |
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Rochester, Minnesota 55905 |
Pfizer Investigational Site | Cincinnait, Ohio 45236 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Richmond, Virginia 23249 |
Pfizer Investigational Site | Federal Way, Washington 98003 |
Pfizer Investigational Site | Flagstaff, Arizona 86001 |
Pfizer Investigational Site | North Little Rock, Arkansas 72117 |
Pfizer Investigational Site | Aurora, Colorado 80012 |
Pfizer Investigational Site | Clearwater, Florida 33761 |
Pfizer Investigational Site | Kansas City, Kansas 66112 |
Pfizer Investigational Site | Westminster, Maryland 21157 |
Pfizer Investigational Site | North Adams, Massachusetts 01247 |
Pfizer Investigational Site | Columbia, Missouri 65201 |
Pfizer Investigational Site | Asheville, North Carolina 28801 |
Pfizer Investigational Site | Bartlesville, Oklahoma 74006 |
Pfizer Investigational Site | Eugene, Oregon 97401 |
Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |
Pfizer Investigational Site | Easley,, South Carolina 29640 |
Pfizer Investigational Site | Farmington, Connecticut 06030-3805 |
Pfizer Investigational Site | Bristol, Tennessee 37620 |
Pfizer Investigational Site | Livingston, New Jersey 07039 |
Pfizer Investigational Site | Washington, District of Columbia 20007-2197 |
Pfizer Investigational Site | Billings, Montana 59101 |
Pfizer Investigational Site | Morgantown, West Virginia 26506 |
Pfizer Investigational Site | Providence, Rhode Island 02906 |